How Natriuretic Peptides Can Guide Heart Failure Treatment in Diabetes Patients
Natriuretic peptides BNP and NT-proBNP serve dual roles in diabetes care — as biomarkers for heart failure risk stratification and as potential guides for targeted cardiovascular therapy.
Quick Facts
What This Study Found
Elevated BNP and NT-proBNP levels in diabetes patients correlate with cardiac abnormalities and can be used for heart failure risk stratification and potentially for guiding treatment strategies.
Key Numbers
Altered SP levels detected in brain, spinal cord, and cerebrospinal fluid of ALS patients and preclinical models.
How They Did This
Narrative review synthesizing evidence on natriuretic peptide biology, diagnostic utility, and therapeutic guidance potential in the context of diabetes and heart failure.
Why This Research Matters
Heart failure is one of the most serious and common complications of diabetes. Natriuretic peptide testing offers a relatively simple blood test that can help identify at-risk patients early and guide treatment intensity.
The Bigger Picture
As the diabetes epidemic continues to grow globally, so does the burden of diabetes-related heart failure. Using natriuretic peptides as both diagnostic and therapeutic guides could help clinicians catch heart problems earlier and treat them more effectively in this high-risk population.
What This Study Doesn't Tell Us
Review article without new primary data; NP-guided therapy evidence is still evolving; NP levels can be influenced by factors beyond cardiac function (obesity, kidney disease); lacks specific treatment algorithms; focused primarily on type 2 diabetes.
Questions This Raises
- ?Should all diabetes patients undergo routine natriuretic peptide screening?
- ?Can NP-guided therapy reduce heart failure hospitalizations in diabetes patients?
- ?How do newer diabetes drugs like SGLT2 inhibitors and GLP-1 agonists affect natriuretic peptide levels?
Trust & Context
- Key Stat:
- BNP/NT-proBNP dual-role peptide biomarkers for heart failure risk and treatment guidance in diabetes
- Evidence Grade:
- Strong evidence for NP as diagnostic/prognostic biomarkers; moderate and evolving evidence for NP-guided therapy in diabetes populations specifically.
- Study Age:
- Published in 2024, reflecting current evidence and emerging perspectives on NP-guided care in diabetes.
- Original Title:
- Perspective role of Substance P in Amyotrophic Lateral Sclerosis: From neuronal vulnerability to neuroprotection.
- Published In:
- Neuroscience and biobehavioral reviews, 167, 105914 (2024)
- Authors:
- Tirassa, Paola, Rosso, Pamela, Fico, Elena, Marenco, Marco, Mallone, Fabiana, Gharbiya, Magda, Lambiase, Alessandro, Severini, Cinzia
- Database ID:
- RPEP-09385
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What are natriuretic peptides and why do they matter for diabetes?
BNP and NT-proBNP are hormones released by your heart when it's stressed or failing. Because diabetes significantly raises heart failure risk, measuring these peptides through a simple blood test can help detect heart problems early — even before symptoms appear.
Should people with diabetes get natriuretic peptide testing?
It's increasingly recommended for diabetes patients at higher cardiovascular risk. Elevated levels signal that the heart may be under stress, allowing doctors to intensify treatment before full-blown heart failure develops.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09385APA
Tirassa, Paola; Rosso, Pamela; Fico, Elena; Marenco, Marco; Mallone, Fabiana; Gharbiya, Magda; Lambiase, Alessandro; Severini, Cinzia. (2024). Perspective role of Substance P in Amyotrophic Lateral Sclerosis: From neuronal vulnerability to neuroprotection.. Neuroscience and biobehavioral reviews, 167, 105914. https://doi.org/10.1016/j.neubiorev.2024.105914
MLA
Tirassa, Paola, et al. "Perspective role of Substance P in Amyotrophic Lateral Sclerosis: From neuronal vulnerability to neuroprotection.." Neuroscience and biobehavioral reviews, 2024. https://doi.org/10.1016/j.neubiorev.2024.105914
RethinkPeptides
RethinkPeptides Research Database. "Perspective role of Substance P in Amyotrophic Lateral Scler..." RPEP-09385. Retrieved from https://rethinkpeptides.com/research/tirassa-2024-perspective-role-of-substance
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.